EUVIMEDEUVIMED entdecken
Crossref

EPIGENETIC REPROGRAMMING IN CANCER PROGRESSION AND THERAPY RESISTANCE

Adewale Adeleke

FRONTIERS IN PHARMACEUTICAL, MEDICAL AND HEALTH SCIENCES · 19.08.2026 · 7 (2) · 28-36

DOI: 10.34218/fpmhs_07_02_002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FRONTIERS IN PHARMACEUTICAL, MEDICAL AND HEALTH SCIENCES, online erschienen am 19.08.2026. Verfasst von Adewale Adeleke.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is no longer understood solely as a genetic disease driven by irreversible mutations; it is increasingly recognized as a dynamic disorder shaped by epigenetic reprogramming.Epigenetic alterations, including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA regulation, play a central role in tumor initiation, progression, metastasis, and resistance to therapy.Unlike genetic mutations, epigenetic changes are reversible, making them attractive therapeutic targets.This review synthesizes current knowledge on how epigenetic reprogramming contributes to cancer progression and therapeutic resistance.It highlights mechanisms by which tumor cells exploit epigenetic plasticity to adapt to environmental stress, evade immune surveillance, and survive anticancer treatments.Additionally, emerging epigenetic therapies and their clinical implications are discussed, emphasizing the need for integrative approaches that combine epigenetic targeting with conventional and precision oncology strategies.

Zitieren

APA

Adeleke, A. (2026). EPIGENETIC REPROGRAMMING IN CANCER PROGRESSION AND THERAPY RESISTANCE. FRONTIERS IN PHARMACEUTICAL, MEDICAL AND HEALTH SCIENCES, 7(2), 28-36. https://doi.org/10.34218/fpmhs_07_02_002

Vancouver

Adeleke A. EPIGENETIC REPROGRAMMING IN CANCER PROGRESSION AND THERAPY RESISTANCE. FRONTIERS IN PHARMACEUTICAL, MEDICAL AND HEALTH SCIENCES. 2026;7(2):28-36. doi:10.34218/fpmhs_07_02_002

BibTeX
@article{Adeleke2026,
  author = {Adeleke, Adewale},
  title = {EPIGENETIC REPROGRAMMING IN CANCER PROGRESSION AND THERAPY RESISTANCE},
  journal = {FRONTIERS IN PHARMACEUTICAL, MEDICAL AND HEALTH SCIENCES},
  year = {2026},
  volume = {7},
  number = {2},
  pages = {28--36},
  doi = {10.34218/fpmhs_07_02_002}
}
Kostenlos starten →